Skip to content
    Font Size
    A
    A
    A

    Prostate Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Evidence of Benefit

    continued...

    The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) is a multicenter, randomized, two-armed trial designed to evaluate the effect of screening for prostate, lung, colorectal, and ovarian cancers on disease-specific mortality. From 1993 through 2001, 76,693 men at ten U.S. study centers were randomly assigned to receive annual screening (38,343 subjects) or usual care as the control (38,350 subjects). Men in the screening group were offered annual PSA testing for 6 years and DRE for 4 years. The subjects and health care providers received the results and decided on the type of follow-up evaluation. Usual care sometimes included screening, as some organizations have recommended.

    In the screening group, rates of compliance were 85% for PSA testing and 86% for DRE. Self-reported rates of screening in the control group increased from 40% in the first year to 52% in the sixth year for PSA testing and ranged from 41% to 46% for DRE. Results from the first four rounds of screening are shown in the Summary of First Four Prostate, Lung, Colorectal, and Ovarian Screening Rounds table.[46]

    Summary of First Four Prostate, Lung, Colorectal, and Ovarian Screening Roundsa

    DRE = digital rectal exam; PSA = prostate-specific antigen; T = tumor.
    a Adapted from Grubb et al.[46]
    T0 (Baseline) T1 T2 T3
    Number Tested (PSA or DRE) 34,262 32,696 31,697 30,544
    PSA positive (>4 ng/mL) (%) 7.9 7.7 8.2 8.8
    DRE positive (%) 7.2 6.8 7.3 7.6
    Either test positive (%) 14.0 13.5 14.4 15.1
    Biopsies and Cancers
    PSA >4 ng/mL 2,718 2,502 2,593 2,676
    Cancers 487 308 270 281
    Cancers/1,000 screened 14.2 9.4 8.5 9.3
    DRE abnormal and PSA ≤4 ng/mL 2,083 1,923 1,973 1,943
    Cancers 62 67 71 57
    Cancers/1,000 screened 1.8 2.1 2.3 1.9
    PSA >4 ng/mL or DRE abnormal 4,801 4,425 4,566 4,619
    Cancers 549 375 341 338
    Cancers/1,000 screened 16.0 11.5 10.8 11.1
    1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22
    1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22
    Next Article:

    Today on WebMD

    man with doctor
    Symptoms, risks, treatments
    man coughing
    Men shouldn’t ignore
     
    prostate cancer cells
    What does this diagnosis mean?
    doctor and male patient
    Is it worth it?
     
    cancer fighting foods
    SLIDESHOW
    15 Cancer Symptoms Men Ignore
    FEATURE
     
    Prostate Enlarged
    VIDEO
    Picture Of The Prostate
    ANATOMY
     
    Prostate Cancer Quiz
    QUIZ
    screening tests for men
    SLIDESHOW
     
    Prostate Cancer Symptoms
    VIDEO
    Vitamin D
    SLIDESHOW